DK3142690T3 - Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist - Google Patents

Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist Download PDF

Info

Publication number
DK3142690T3
DK3142690T3 DK15733563.9T DK15733563T DK3142690T3 DK 3142690 T3 DK3142690 T3 DK 3142690T3 DK 15733563 T DK15733563 T DK 15733563T DK 3142690 T3 DK3142690 T3 DK 3142690T3
Authority
DK
Denmark
Prior art keywords
moleculate
agonist
antagonist
combination therapy
treating cancer
Prior art date
Application number
DK15733563.9T
Other languages
Danish (da)
English (en)
Inventor
Susan Foy
Stefanie Mandl
Ryan Rountree
Alex Franzusoff
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK3142690T3 publication Critical patent/DK3142690T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK15733563.9T 2014-05-13 2015-05-08 Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist DK3142690T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992788P 2014-05-13 2014-05-13
PCT/US2015/029855 WO2015175334A2 (en) 2014-05-13 2015-05-08 Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist

Publications (1)

Publication Number Publication Date
DK3142690T3 true DK3142690T3 (da) 2022-05-09

Family

ID=53499070

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15733563.9T DK3142690T3 (da) 2014-05-13 2015-05-08 Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist

Country Status (13)

Country Link
US (1) US20170266270A1 (https=)
EP (1) EP3142690B1 (https=)
JP (1) JP6747981B2 (https=)
KR (1) KR102499737B1 (https=)
CN (1) CN106456747A (https=)
AU (1) AU2015259510B2 (https=)
CA (1) CA2946418C (https=)
DK (1) DK3142690T3 (https=)
ES (1) ES2913236T3 (https=)
IL (1) IL248507B (https=)
NZ (1) NZ725459A (https=)
RU (1) RU2724433C2 (https=)
WO (1) WO2015175334A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2015289081B2 (en) * 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) * 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
JP7025339B2 (ja) 2016-02-25 2022-02-24 メモリアル スローン ケタリング キャンサー センター 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
US20210198689A1 (en) * 2016-03-18 2021-07-01 Nant Holdings Ip, Llc Multimodal Vector for Dendritic Cell Infection
EP3225253A1 (en) * 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
CN107281474A (zh) * 2016-04-11 2017-10-24 中国科学院上海巴斯德研究所 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物
WO2017207814A1 (en) 2016-06-02 2017-12-07 Ultimovacs As A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
HUE057559T2 (hu) * 2016-11-02 2022-06-28 Jounce Therapeutics Inc PD-1 elleni antitestek és alkalmazásaik
KR200486872Y1 (ko) 2016-11-16 2018-07-10 김영선 가변형 조립식 책상
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
KR102754876B1 (ko) * 2017-08-24 2025-01-13 버베리안 노딕 에이/에스 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법
WO2019090343A1 (en) * 2017-11-06 2019-05-09 Memorial Sloan Kettering Cancer Center Heat-inactivated vaccinia virus as a vaccine immune adjuvant
WO2019152922A1 (en) * 2018-02-05 2019-08-08 Nant Holdings Ip, Llc Calreticulin and fusion proteins
TWI905535B (zh) * 2018-04-23 2025-11-21 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
US11564980B2 (en) 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
BR112021004692A2 (pt) 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center poxvírus recombinantes para imunoterapia de câncer
MX2021005560A (es) 2018-11-20 2021-06-23 Bavarian Nordic As Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l).
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3941514A4 (en) * 2019-03-20 2023-08-30 Turnstone Biologics Inc. ONCOLYTIC VIROTHERAPY BY HETEROLOGY SEQUENTIAL BOOSTER
JP7732977B2 (ja) 2019-09-20 2025-09-02 トランスジーン Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
CN114929268A (zh) * 2019-11-20 2022-08-19 巴法里安诺迪克有限公司 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途
CN114867491B (zh) * 2019-11-20 2025-08-15 巴法里安诺迪克有限公司 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1119354A (en) * 1914-01-05 1914-12-01 Adelbert Armstrong Broom-holder.
US1391972A (en) * 1920-08-05 1921-09-27 American Cotton Oil Company Method and apparatus for molding soap
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами

Also Published As

Publication number Publication date
EP3142690B1 (en) 2022-02-23
NZ725459A (en) 2023-04-28
RU2016148311A (ru) 2018-06-18
WO2015175334A3 (en) 2016-02-04
RU2016148311A3 (https=) 2018-12-26
JP2017515837A (ja) 2017-06-15
IL248507A0 (en) 2016-12-29
JP6747981B2 (ja) 2020-08-26
AU2015259510A1 (en) 2016-11-10
CA2946418C (en) 2023-07-04
WO2015175334A2 (en) 2015-11-19
CN106456747A (zh) 2017-02-22
ES2913236T3 (es) 2022-06-01
EP3142690A2 (en) 2017-03-22
AU2015259510B2 (en) 2020-10-01
IL248507B (en) 2022-07-01
RU2724433C2 (ru) 2020-06-23
KR20170003556A (ko) 2017-01-09
US20170266270A1 (en) 2017-09-21
KR102499737B1 (ko) 2023-02-13
CA2946418A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
DK3142690T3 (da) Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist
DK3065770T3 (da) Kombinationsterapi til behandling af cancer med et poxvirus, der udtrykker et tumorantigen og en antagonist af en immuncheckpoint-inhibitor
IL297418B1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
IL260033A (en) A virus that encodes an antibody or anti-tcr-complex particle
DK3142689T3 (da) Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3
IL254214A0 (en) Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
IL253658A0 (en) Combined treatment with coagulation factors and multispecific antibodies
DK3303394T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
IL258448B1 (en) Antigen-binding proteins that activate the leptin receptor
DK3313882T3 (da) Anti-VISTA antistoffer og fragmenter
DK3182999T3 (da) Anti-lag3-antistoffer og antigenbindingsfragmenter
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3294770T3 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
HUE046505T2 (hu) Antitestkészítmények daganatkezelésre
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
EP3256156C0 (en) IMMUNOTHERAPY VACCINE AND ANTIBODY-BASED COMBINATION THERAPY
DK2971045T3 (da) Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen
DK3324986T3 (da) Materialer og fremgangsmåder til forbedring af immunreaktioner og hud- og/eller slimhindebarrierefunktion
DK3169703T3 (da) Kimær antigenreceptor og anvendelse deraf
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
DK3253800T3 (da) Prostata antigen standarder og bruge deraf
EP3385286A4 (en) VACCINE FANTASY WITH INCREASED IMMUNOGENITY
DK3273986T3 (da) Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
DK3219726T3 (da) Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf